AbbVie - Stock Price History | ABBV

Historical daily share price chart and data for AbbVie since 2022 adjusted for splits. The latest closing stock price for AbbVie as of August 18, 2022 is 141.29.
  • The all-time high AbbVie stock closing price was 171.81 on April 08, 2022.
  • The AbbVie 52-week high stock price is 175.91, which is 24.5% above the current share price.
  • The AbbVie 52-week low stock price is 105.56, which is 25.3% below the current share price.
  • The average AbbVie stock price for the last 52 weeks is 136.57.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AbbVie Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 107.8937 97.7615 132.0888 95.9821 131.5738 32.40%
2020 82.6029 78.7623 100.7850 57.4889 99.3753 27.61%
2019 66.9863 74.2630 79.3780 54.5996 77.8740 1.50%
2018 79.7248 78.8481 99.4245 64.7919 76.7265 -0.98%
2017 59.5361 48.2275 78.6879 46.8506 77.4861 60.13%
2016 46.2155 42.8279 51.5954 38.4715 48.3898 9.88%
2015 45.5408 47.4057 52.4559 35.8844 44.0397 -6.46%
2014 39.4361 36.2122 50.1540 32.8863 47.0819 27.97%
2013 30.0181 23.5360 37.8424 22.5910 36.7904 0.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $250.080B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $440.598B 16.77
Eli Lilly (LLY) United States $301.034B 38.17
Pfizer (PFE) United States $276.521B 8.10
Novo Nordisk (NVO) Denmark $237.182B 31.29
Merck (MRK) United States $230.630B 12.04
Novartis AG (NVS) Switzerland $188.558B 13.90